fospropofol disodium
Phase 3Small molecule
Eisaifospropofol disodium is one of 19 small molecule programs targeting Anesthesia. It is currently in Phase 3.
2
Indications
13
Total Trials
3
Active Trials
18
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
30 competitors in Anesthesia
#DrugCompanyPhaseTrials
1Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Versed
CConrado Roberto Hoffmann Filho
Approved
Sufenta
LLeaf Vertical Inc.
Approved
Iheezo
BB. Braun Medical Inc.
Approved
Xylocaine
MMEDRx USA, Inc.
Phase 1
Ultiva
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 1
fospropofol disodium
EisaiPhase 3
Duragesic
CCephalon
Preclinical
Romazicon
CConrado Roberto Hoffmann Filho
Preclinical
Ultram
WWim Janssens
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sedation6 trials
Show 3 more trials
Medication1 trial
Safety and Efficacy1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for fospropofol disodium. EMBL-EBI & Wellcome Sanger Institute.
- [4]